These Billionaire Michael Price’s Stock Picks Can Destroy Your Portfolio

MFP sold 200,000 shares of Boston Scientific Corporation (NYSE:BSX) during the third quarter, and held 700,000 shares valued at $16.66 million. The stock has gained over 16% year-to-date. Boston Scientific Corporation (NYSE:BSX) recently has filed a patent infringement suit against Nevro Corp. (NYSE:NVRO), claiming that Nevro’s Senza neuromodulation system infringes Boston Scientific’s patents on leads, batteries and telemetry unit. Boston Scientific recently completed its $75 million acquisition of Neovasc, Inc., (NASDAQ: NVCN)’s advanced biologic tissue capabilities and certain manufacturing assets. Samuel Isaly’s OrbiMed Advisors owns 17.21 million shares of Boston Scientific Corporation (NYSE:BSX) as of the end of the third quarter. Overall, 46 investors tracked by us amassed shares of Boston Scientific Corporation at the end of September.

Follow Boston Scientific Corp (NYSE:BSX)

MFP Investors upped its stake in Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) by 6% to 469,300 shares worth $21.59 million during the third quarter. Earlier this month, Teva announced the appointment of Dipankar Bhattacharjee as the head of its global generic medicine group. Mr. Bhattacharjee, who has been the chief executive of Teva Generics Europe since 2013, will replace Siggi Olafsson. This management change surprised investors and the stock tanked, as Siggi Olafsson was the key figure behind Teva’s $33.5 billion acquisition of Actavis. Last month, Morgan Stanley downed its rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s stock to ‘Equal Weight’ from Overweight’ and also slashed its price target to $42 from $63. Of the 742 hedge funds in our database, 54 were bullish on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) at the end of the third quarter, down by one over the quarter.

Follow Apple Inc. (NASDAQ:AAPL)

MFP Investors reported ownership of 1.8 million shares of Intel Corporation (NASDAQ:INTCworth $67.95 million as of the end of September. The stock is up over 7% year-to-date. Intel recently announced development-focused Artificial Intelligence platform, Nervana, to enable data scientists and professionals in the tech industry to solve the “world’s biggest challenges”. The world’s biggest chipmaker in terms of revenue is also making a huge bet on the Cloud and Artificial Intelligence industry with its Saffron Technology, which leverages memory-based reasoning techniques to analyze and use heterogeneous data. Natixis Global Asset Management’s Harris Associates disclosed 20.69 million shares of Intel Corporation (NASDAQ:INTC) in its latest 13F filing. During the third quarter, the number of funds from our database long Intel Corporation (NASDAQ:INTC) went up by nine to 68.

Follow Intel Corp (NASDAQ:INTC)


Disclosure: None